8-K 1 pal229671.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): February 8, 2007

 

Genelabs Technologies, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

California

 

0-19222

 

94-3010150

(State or other jurisdiction
of incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

 

 

505 Penobscot Drive, Redwood City, California

 

94063

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (650) 369-9500

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

o

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 8.01. Other Events.

 

On February 8, 2007, Genelabs issued a press release announcing an agreement to raise $10.0 million in private placement financing. It will sell approximately 5.8 million shares of its common stock and warrants to purchase approximately 1.7 million shares of its common stock to institutional investors and accredited investors for $1.72 per share (which includes the warrant purchase price of $0.125 per share underlying the warrants), with a warrant exercise price of $1.85 per share. The full text of the Genelabs press release is furnished as Exhibit 99.1 hereto to this Current Report on Form 8-K, and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits

 

(c) Exhibits

 

Exhibit Number

Description

 

99.1

 

Press Release of Registrant, dated February 8, 2007, entitled "Genelabs Technologies Announces Agreement to Raise $10 Million in Private Placement Financing"

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Genelabs Technologies, Inc.

Date: February 8, 2007

 

By:

/s/ James A.D. Smith

 

 

Name:

James A.D. Smith

 

 

Title:

President and Chief Executive Officer

 

 

 

EXHIBIT INDEX

 

Exhibit Number

Description

 

99.1

 

Press Release of Registrant, dated Februrary 8, 2007, "Genelabs Technologies Announces Agreement to Raise $10 Million in Private Placement Financing"